HC Wainwright restated their buy rating on shares of LB Pharmaceuticals (NASDAQ:LBRX – Free Report) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($1.07) EPS, […]

HC Wainwright reaffirmed their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings […]